Loading clinical trials...

TERMINATEDPHASE2

A Scintigraphy Study in Adults With Diabetic Gastroparesis

A Randomized, Double-Blind Placebo-Controlled Scintigraphy Study to Investigate the Effect of CIN-102 on Gastric Emptying and Antral Contractility in Adults With Diabetic Gastroparesis

NCT04208698•CinDome Pharma, Inc.

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.

Detailed Description

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis. The population for this study is adult patients 18 to 70 years old with Type 1 or Type 2 diabetes and a diagnosis of diabetic gastroparesis. The study will consist of two cohorts with approximately 15 subjects in each cohort.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female patients 18 to 70 years old, inclusive.
•Type 1 or Type 2 diabetes mellitus, according to American Diabetes Association criteria
•Current diagnosis of diabetic gastroparesis.
•Body Mass Index (BMI) between 18 and 40 kg/m2, inclusive.
•Glycosylated hemoglobin level \<11% at Screening.
•Willing to abstain from tobacco or nicotine-containing product use after midnight on the day of the DAS test and throughout the time that gastric emptying is being imaged.
•Willing to abstain from grapefruit, grapefruit products, star fruit, star fruit products, and Seville oranges from 72 hours prior to the Randomization Visit until end of study.

Exclusion Criteria

•History of, or current, clinically significant arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, and Torsades de Pointes. Patients with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded.
•Clinically significant bradycardia with a resting heart rate under 50 beats per minute, sinus node dysfunction, or heart block.
•Prolonged heart rate-corrected QT interval using Fridericia's formula (QTcF) (QTcF \>450 msec for males or QTcF \>470 msec for females) based on the average of triplicate ECGs.
•A personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias or family history of sudden death.
•Evidence (based on Screening or Baseline assessments) or history of clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies); surgical conditions; cancer (with the exception of basal or squamous cell carcinoma of the skin and cancer that resolved or has been in remission for \>5 years prior to the Screening Visit); or any condition that, in the Investigator's opinion, might significantly interfere with the absorption, distribution, metabolism, or excretion of the study drug.
•History of prolactin-releasing pituitary tumor (ie, prolactinoma).
•Allergic to egg or intolerant to gluten.
•History of alcoholism or drug abuse within 2 years prior to dosing as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.
•Known or suspected gastric outlet obstruction (eg, peptic stricture) or other gastrointestinal mechanical obstruction.
•Known history or current diagnosis of intestinal malabsorption or pancreatic exocrine disease.
+2 more criteria

Locations (1)

Research Site

El Paso, Texas, United States

Key Dates

Start Date

February 17, 2020

Primary Completion Date

March 31, 2020

Completion Date

March 31, 2020

Last Updated

August 10, 2021

Enrollment

ACTUAL participants

Conditions

Diabetic Gastroparesis

Interventions

CIN-102 Dose 1

DRUG

CIN-102 Dose 2

DRUG

Placebo for CIN-102

DRUG

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

NCT04028492

Idiopathic GastroparesisDiabetic Gastroparesis+1 more

View study

NOT_YET_RECRUITINGNA

Washed Microbiota Transplantation Alleviates Diabetic Gastrointestinal Motility Disorders: an Efficacy and Safety Study

NCT06340828

Diabetic GastroparesisDiabetic Gastropathy+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 10, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Scintigraphy Study in Adults With Diabetic Gastroparesis

Inclusion Criteria

Exclusion Criteria

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Washed Microbiota Transplantation Alleviates Diabetic Gastrointestinal Motility Disorders: an Efficacy and Safety Study

A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis